Used in pharmaceutical research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving dysregulated dopamine signaling. It modulates intracellular cAMP and cGMP levels in the brain, especially in the striatum, which plays a key role in motor control and cognition. Due to its ability to cross the blood-brain barrier and exhibit favorable pharmacokinetic properties in preclinical models, it serves as a valuable tool compound for studying PDE10A-related pathways and as a candidate for developing antipsychotic therapies with improved side effect profiles.